"Jur\u010Dovi\u010Dov\u00E1, Jana" . "RIV/00216208:11110/13:10190229!RIV14-GA0-11110___" . "NPY/AgRP; Food intake; Male C57BL/6 mice; JMV 1843; GHS-R agonists"@en . "76597" . "4" . . . "Martinez, J." . . "0862-8408" . . "3"^^ . . "Ghrelin Agonist JMV 1843 Increases Food Intake, Body Weight and Expression of Orexigenic Neuropeptides in Mice" . . "\u017Delezn\u00E1, B." . "Lacinov\u00E1, Zde\u0148ka" . "Ghrelin Agonist JMV 1843 Increases Food Intake, Body Weight and Expression of Orexigenic Neuropeptides in Mice" . . . . . "Ghrelin Agonist JMV 1843 Increases Food Intake, Body Weight and Expression of Orexigenic Neuropeptides in Mice"@en . "[A8851F9C48F8]" . . "000323510500011" . "Ghrelin and agonists of its receptor GHS-R1a are potential substances for the treatment of cachexia. In the present study, we investigated the acute and long-term effects of the GHS-R1a agonist JMV 1843 (H-Aib-DTrp-D-gTrp-CHO) on food intake, body weight and metabolic parameters in lean C57BL/6 male mice. Additionally, we examined stability of JMV 1843 in mouse blood serum. A single subcutaneous injection of JMV 1843 (0.01-10 mg/kg) increased food intake in fed mice in a dose-dependent manner, up to 5-times relative to the saline-treated group (ED50=1.94 mg/kg at 250 min). JMV 1843 was stable in mouse serum in vitro for 24 h, but was mostly eliminated from mouse blood after 2 h in vivo. Ten days of treatment with JMV 1843 (subcutaneous administration, 10 or 20 mg/kg/day) significantly increased food intake, body weight and mRNA expression of the orexigenic neuropeptide Y and agouti-related peptide in the medial basal hypothalamus and decreased the expression of uncoupling protein 1 in brown adipose tissue. Our data suggest that JMV 1843 could have possible future uses in the treatment of cachexia." . "Holubov\u00E1, M." . "11110" . . "Dr\u00E1palov\u00E1, Jana" . "CZ - \u010Cesk\u00E1 republika" . . . "Ghrelin and agonists of its receptor GHS-R1a are potential substances for the treatment of cachexia. In the present study, we investigated the acute and long-term effects of the GHS-R1a agonist JMV 1843 (H-Aib-DTrp-D-gTrp-CHO) on food intake, body weight and metabolic parameters in lean C57BL/6 male mice. Additionally, we examined stability of JMV 1843 in mouse blood serum. A single subcutaneous injection of JMV 1843 (0.01-10 mg/kg) increased food intake in fed mice in a dose-dependent manner, up to 5-times relative to the saline-treated group (ED50=1.94 mg/kg at 250 min). JMV 1843 was stable in mouse serum in vitro for 24 h, but was mostly eliminated from mouse blood after 2 h in vivo. Ten days of treatment with JMV 1843 (subcutaneous administration, 10 or 20 mg/kg/day) significantly increased food intake, body weight and mRNA expression of the orexigenic neuropeptide Y and agouti-related peptide in the medial basal hypothalamus and decreased the expression of uncoupling protein 1 in brown adipose tissue. Our data suggest that JMV 1843 could have possible future uses in the treatment of cachexia."@en . "S\u00FDkora, D." . . "62" . "Malet\u00EDnsk\u00E1, L." . "http://www.biomed.cas.cz/physiolres/pdf/62/62_435.pdf" . . . "Physiological Research" . "I, P(GA303/09/0744), P(GAP303/10/1368), Z(MSM6046137307)" . "Demianov\u00E1, Z." . . . . "Fehrentz, J. A." . "13"^^ . "\u0160tofkov\u00E1, Andrea" . . "Ghrelin Agonist JMV 1843 Increases Food Intake, Body Weight and Expression of Orexigenic Neuropeptides in Mice"@en . "RIV/00216208:11110/13:10190229" . . "\u0160polcov\u00E1, A." . . . "Haluz\u00EDk, Martin" . "10"^^ .